Figure 8.

Validation of PC-SA Liposomes on PBMCs of Leukemia Patients and K562 Xenograft Model in Nude Mice

(A) PBMCs from 3 primary acute myeloid and promyelocytic leukemia patients were cultured in medium with graded doses of PC-SA liposomes for 2 hr, and cell viability was determined by MTT. (B and C) K562 cells embedded in Matrigel were staged in nude mice. On days 7 and 16, mice were administered 60 mg/kg of PC-SA liposomes alone, 2.8 mg/kg of free DOX, and 2.8 mg/kg of DOX entrapped in 60 mg/kg of PC-SA liposomes subcutaneously and sacrificed (B) on day 24 to measure the tumor growth (C). Data represent mean ± SE for three animals per group performed in duplicate.